tiprankstipranks
Qiagen enters strategic partnership with Servier
The Fly

Qiagen enters strategic partnership with Servier

Qiagen announced it has entered into a strategic partnership with Servier, a pharmaceutical group, to develop a companion diagnostic test for Tibsovo, an isocitrate dehydrogenase-1, or IDH1, inhibitor indicated for the treatment of the blood cancer acute myeloid leukemia, or AML. Under the master collaboration agreement, Qiagen will develop and validate a real-time in vitro PCR test that can be used to detect IDH1 gene mutations in AML patients in whole blood and bone marrow aspirates. The companion diagnostic will run on the QIAGEN Rotor-Gene Q MDx device, which is widely used by labs worldwide. QIAGEN’s experienced regulatory teams will support clinical validation of the companion diagnostic and its approval in the U.S., the European Union and Japan.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on QGEN:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles